Mersana Therapeutics Inc. (MRSN)
NASDAQ: MRSN
· Real-Time Price · USD
0.40
-0.03 (-7.60%)
At close: May 01, 2025, 3:59 PM
-7.60% (1D)
| Bid | 0.38 |
| Market Cap | 49.84M |
| Revenue (ttm) | 40.5M |
| Net Income (ttm) | -69.19M |
| EPS (ttm) | -0.63 |
| PE Ratio (ttm) | -0.63 |
| Forward PE | -0.63 |
| Analyst | Buy |
| Ask | 0.43 |
| Volume | 2,220,471 |
| Avg. Volume (20D) | 3,503,449 |
| Open | 0.43 |
| Previous Close | 0.43 |
| Day's Range | 0.38 - 0.43 |
| 52-Week Range | 0.26 - 3.63 |
| Beta | 1.67 |
About MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2017
Employees 102
Stock Exchange NASDAQ
Ticker Symbol MRSN
Website https://www.mersana.com
Analyst Forecast
According to 3 analyst ratings, the average rating for MRSN stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 900.25% from the latest price.
Stock ForecastsNext Earnings Release
Mersana Therapeutics Inc. is scheduled to release its earnings on May 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-44.62%
Mersana Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
5 months ago
+19.55%
Mersana Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
